Esperion Therapeutics, Inc. (ESPR)
2.55
-0.05
(-1.92%)
USD |
NASDAQ |
Mar 20, 16:00
2.55
0.00 (0.00%)
After-Hours: 20:00
Esperion Therapeutics Research and Development Expense (Quarterly) : 13.93M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Nektar Therapeutics | 29.68M |
| Harrow, Inc. | 3.273M |
| Catalyst Pharmaceuticals, Inc. | 1.807M |
| Rigel Pharmaceuticals, Inc. | 10.68M |
| CytomX Therapeutics, Inc. | 20.76M |